The Novartis business will be a drain on profits for FY16, and FY17. FY18 will be flat. This story has been well publicised, and I think the market will look to the outlook forecast more than the reduced eps, as well as the potential of another share buyback.
See what happens when the market opens.
HT1
Ann: 2016 FY Results Announcements and Analysts Briefing-CSL.AX, page-7
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$301.51 |
Change
1.100(0.37%) |
Mkt cap ! $145.9B | |||
| Open | High | Low | Value | Volume |
| $301.49 | $303.53 | $301.43 | $205.6M | 681.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 518 | $301.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $301.64 | 1548 | 1 |
View Market Depth
| Last trade - 16.10pm 10/09/2024 (20 minute delay) ? |
| CSL (ASX) Chart |